• Hematologic Malignancy Clinical Trials

    Our scientists and physicians conduct extensive laboratory and clinical research to identify new treatments and improve therapies for children with hematologic malignancies. Our team’s achievements include:

    • Improving leukemia cure rates and reducing chemotherapy-associated side effects
    • Developing treatment protocols that offer the best published cure rates for children with acute lymphoblastic leukemia
    • Conducting innovative clinical trials of new, promising agents in children with relapsed and refractory leukemia and lymphoma
    • Reducing the risk of late effects of treatment (learning disabilities, heart dysfunction and bone problems) in leukemia survivors
    • Discovering unique genetic mutations associated with histiocytosis and working to develop treatments based on this discovery

    We lead an internationally recognized clinical trials consortium for children and adolescents with newly diagnosed acute lymphoblastic leukemia – the DFCI ALL Consortium – consisting of 9 institutions in the United States and Canada. We are a founding member of a small national consortium of leading medical centers that investigate new treatments for children with Hodgkin lymphoma, including innovative drug combinations (and reduced exposure to radiation) that deliver results with fewer long-term complications. In addition, we participate in clinical trials conducted by the Histiocyte Society for patients with Langerhans Cell Histiocytosis.

    To inquire about clinical trials, email us at clinicaltrials@danafarberbostonchildrens.org and read our clinical trial FAQ for answers to general questions.

    Featured Leukemia Clinical Trials

    This trial investigates how Everolimus works in combination with other drugs that are commonly used to treat relapsed acute lymphoblastic leukemia (prednisone, vincristine, PEG-asparaginase, and doxorubicin). The main goal of the study is to evaluate the side effects of this treatment combination in order to determine a safe dose of Everolimus which can be given with these other 4 drugs. PI: Lewis B. Silverman, MD

    This precision medicine study will determine whether it is possible to use profiling results to determine a matched targeted therapy for children and young adults with high-risk leukemia (including relapsed acute lymphoblastic leukemia and acute myelogenous leukemia). It will investigate the range of mutations found in children with high-risk leukemia, and describe the clinical outcomes of patients who receive a matched targeted therapy. PI: Yana Pikman, MD

     

    Search Trials by Condition

    Search trials by condition using the links below, or see our clinical trials for relapsed cancer available through our Advancing Childhood Cancer Therapies (ACCT) Clinic.
  • Contact Us

    Call 1-855-320-2092. We can answer questions about treatment or new patient scheduling.
  • Hematologic Malignancy Clinical Trials

    Search our wide range of clinical trials for hematologic malignancies, including lymphoma, leukemia and histiocytosis. callout bg
  • Clinical Trials for Relapsed Cancer

    acct programFor patients with relapsed, refractory, or recurrent cancer, early phase clinical trials may be a treatment option.
  • Know Your Options

    Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
    We can help you navigate your options.
  • Stay Informed

     

    Stay informed about our clinical trials research efforts. Sign up for our email newsletter Advances in Pediatric Hematology/Oncology.